Sam H. Whiting

551 total citations
20 papers, 361 citations indexed

About

Sam H. Whiting is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Cancer Research. According to data from OpenAlex, Sam H. Whiting has authored 20 papers receiving a total of 361 indexed citations (citations by other indexed papers that have themselves been cited), including 8 papers in Oncology, 7 papers in Pulmonary and Respiratory Medicine and 6 papers in Cancer Research. Recurrent topics in Sam H. Whiting's work include Cancer, Hypoxia, and Metabolism (4 papers), Colorectal Cancer Treatments and Studies (4 papers) and Virus-based gene therapy research (3 papers). Sam H. Whiting is often cited by papers focused on Cancer, Hypoxia, and Metabolism (4 papers), Colorectal Cancer Treatments and Studies (4 papers) and Virus-based gene therapy research (3 papers). Sam H. Whiting collaborates with scholars based in United States, France and United Kingdom. Sam H. Whiting's co-authors include Thomas Folkmann Hansen, Eric Barklis, John Nemunaitis, Neil Senzer, Robert Mennel, Beena O. Pappen, Minal Barve, Gladice Wallraven, Carl Lenarsky and Staci Horvath and has published in prestigious journals such as Science, Journal of Clinical Oncology and Cancer Research.

In The Last Decade

Sam H. Whiting

18 papers receiving 355 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Sam H. Whiting United States 9 153 141 109 85 76 20 361
Karl-Henning Kalland Norway 10 247 1.6× 70 0.5× 149 1.4× 99 1.2× 26 0.3× 13 402
Federica Alessandrini Italy 9 143 0.9× 75 0.5× 57 0.5× 25 0.3× 58 0.8× 13 319
Baocheng Hu United States 9 326 2.1× 134 1.0× 110 1.0× 29 0.3× 26 0.3× 16 396
Si-Yi Chen United States 8 169 1.1× 127 0.9× 104 1.0× 78 0.9× 170 2.2× 12 390
Alexandra Dananberg United States 5 221 1.4× 80 0.6× 95 0.9× 20 0.2× 69 0.9× 8 317
Patrick von Morgen Czechia 8 318 2.1× 103 0.7× 81 0.7× 22 0.3× 92 1.2× 8 410
Cécile Desjobert France 13 357 2.3× 54 0.4× 143 1.3× 32 0.4× 48 0.6× 16 504
Kejun Li China 13 387 2.5× 89 0.6× 344 3.2× 27 0.3× 76 1.0× 21 609
Kevan Chu United States 3 267 1.7× 74 0.5× 103 0.9× 18 0.2× 100 1.3× 6 365
Jennifer A. Fairley United Kingdom 13 343 2.2× 106 0.8× 157 1.4× 53 0.6× 36 0.5× 23 532

Countries citing papers authored by Sam H. Whiting

Since Specialization
Citations

This map shows the geographic impact of Sam H. Whiting's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Sam H. Whiting with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Sam H. Whiting more than expected).

Fields of papers citing papers by Sam H. Whiting

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Sam H. Whiting. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Sam H. Whiting. The network helps show where Sam H. Whiting may publish in the future.

Co-authorship network of co-authors of Sam H. Whiting

This figure shows the co-authorship network connecting the top 25 collaborators of Sam H. Whiting. A scholar is included among the top collaborators of Sam H. Whiting based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Sam H. Whiting. Sam H. Whiting is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Yarchoan, Mark, John D. Powderly, Bruno R. Bastos, et al.. (2024). First-in-human Phase I Trial of TPST-1120, an Inhibitor of PPARα, as Monotherapy or in Combination with Nivolumab, in Patients with Advanced Solid Tumors. Cancer Research Communications. 4(4). 1100–1110. 11 indexed citations
2.
Ulahannan, Susanna V., John D. Powderly, Melissa L. Johnson, et al.. (2023). A phase 1 study of TPST-1495 as a single agent and in combination with pembrolizumab in patients with advanced solid tumors.. Journal of Clinical Oncology. 41(16_suppl). 3107–3107. 5 indexed citations
3.
Coveler, Andrew L., Venu G. Pillarisetty, Wui‐Jin Koh, et al.. (2023). Perioperative Chemotherapy and Chemoradiotherapy for Patients With Resectable and Borderline Resectable Pancreatic Adenocarcinoma. Pancreas. 52(5). e282–e287.
4.
Francica, Brian J., Justine Lopez, Anja Holtz, et al.. (2022). Abstract 1333: Dual blockade of the EP2 and EP4 PGE2 receptors with TPST-1495 is an optimal approach for drugging the prostaglandin pathway. Cancer Research. 82(12_Supplement). 1333–1333. 1 indexed citations
5.
Yarchoan, Mark, John D. Powderly, Bruno R. Bastos, et al.. (2022). A phase 1 study of TPST-1120 as a single agent and in combination with nivolumab in subjects with advanced solid tumors.. Journal of Clinical Oncology. 40(16_suppl). 3005–3005. 5 indexed citations
6.
Davar, Diwakar, John D. Powderly, Susanna V. Ulahannan, et al.. (2022). A phase 1 study of TPST-1495 as a single agent and in combination with pembrolizumab in subjects with solid tumors.. Journal of Clinical Oncology. 40(16_suppl). TPS2696–TPS2696. 5 indexed citations
7.
8.
Whiting, Sam H., et al.. (2019). P023 Improving parenteral nutrition prescribing. Archives of Disease in Childhood. 104(7). e2.27–e2. 1 indexed citations
9.
Meric‐Bernstam, Funda, Richard J. Lee, Bradley Curtis Carthon, et al.. (2019). CB-839, a glutaminase inhibitor, in combination with cabozantinib in patients with clear cell and papillary metastatic renal cell cancer (mRCC): Results of a phase I study.. Journal of Clinical Oncology. 37(7_suppl). 549–549. 41 indexed citations
10.
Motzer, Robert J., Chung‐Han Lee, Hamid Emamekhoo, et al.. (2019). ENTRATA: Randomized, double-blind, phase II study of telaglenastat (tela; CB-839) + everolimus (E) vs placebo (pbo) + E in patients (pts) with advanced/metastatic renal cell carcinoma (mRCC). Annals of Oncology. 30. v889–v890. 22 indexed citations
11.
Ciombor, Kristen K., Jennifer G. Whisenant, Dana B. Cardin, et al.. (2019). CB-839, panitumumab, and irinotecan in RAS wildtype (WT) metastatic colorectal cancer (mCRC): Phase I results.. Journal of Clinical Oncology. 37(4_suppl). 574–574. 5 indexed citations
12.
Barve, Minal, Robert Mennel, Carl Lenarsky, et al.. (2016). Three-year Follow up of GMCSF/bi-shRNAfurin DNA-transfected Autologous Tumor Immunotherapy (Vigil) in Metastatic Advanced Ewing's Sarcoma. Molecular Therapy. 24(8). 1478–1483. 71 indexed citations
13.
Meric‐Bernstam, Funda, Nizar M. Tannir, James J. Harding, et al.. (2016). Phase 1 study of CB-839, a small molecule inhibitor of glutaminase, in combination with everolimus in patients (pts) with clear cell and papillary renal cell cancer (RCC). European Journal of Cancer. 69. S12–S13. 9 indexed citations
14.
Barve, Minal, Reva Schneider, Robert Mennel, et al.. (2015). Pilot Trial of FANG Immunotherapy in Ewing's Sarcoma. Molecular Therapy. 23(6). 1103–1109. 48 indexed citations
15.
16.
Nemunaitis, John, Cynthia Bedell, Kevin Klucher, Alex Vo, & Sam H. Whiting. (2013). Phase 1 dose escalation of ONT-10, a therapeutic MUC1 vaccine, in patients with advanced cancer. Journal for ImmunoTherapy of Cancer. 1(S1). 11 indexed citations
17.
Safran, Howard, Thomas J. Miner, Nathan Bahary, et al.. (2010). Lapatinib and Gemcitabine for Metastatic Pancreatic Cancer. American Journal of Clinical Oncology. 34(1). 50–52. 36 indexed citations
18.
Whiting, Sam H.. (1995). Faltering Press Embargo?. Science. 270(5233). 13–13. 1 indexed citations
19.
Macé, Muriel, et al.. (1992). Retroviral envelope protein fusions to secreted and membrane markers. Virology. 188(2). 869–874. 6 indexed citations
20.
Hansen, Thomas Folkmann, et al.. (1990). Transport and assembly of gag proteins into Moloney murine leukemia virus. Journal of Virology. 64(11). 5306–5316. 78 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Karl-Henning Kalland Breakdown of academic impact, for papers by Federica Alessandrini Breakdown of academic impact, for papers by Baocheng Hu Breakdown of academic impact, for papers by Si-Yi Chen Breakdown of academic impact, for papers by Alexandra Dananberg Breakdown of academic impact, for papers by Patrick von Morgen Breakdown of academic impact, for papers by Cécile Desjobert Breakdown of academic impact, for papers by Kejun Li Breakdown of academic impact, for papers by Kevan Chu Breakdown of academic impact, for papers by Jennifer A. Fairley
Rankless by CCL
2026